Please assess the completion status of the following clinical trial:

Trial Title: MAGNET CRT Feasibility - Efficiency of LV Lead Placement Comparing Conventional vs. Magnetic Guidance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria/Exclusion Criteria:~1. The patient is 18 years of age or older.~2. The patient is clinically indicated for left ventricular lead placement as part of a pacing or defibrillator system.~3. The patient may be safely exposed to magnetic fields that exist in Niobe® MNS laboratory.~4. The patient is not participating in any clinical trial or studies that would conflict with the guidewire navigation/LV lead implant protocol for this study.~5. The patient is not pregnant, and if of childbearing potential has completed a pregnancy test which resulted negative.~6. The patient does not have an implanted pacemaker or defibrillator, unless such device will be explanted or otherwise deactivated during this procedure.~7. The patient has no contraindications for contrast dye injection.~8. The patient's diastolic blood pressure is greater than 40 mm Hg.~9. In the opinion of the investigator, the patient's general health status does not preclude participation in the study.~10. In the opinion of the investigator, the patient is a reasonable candidate for participation in this study.~11. The patient is not expected to undergo a heart transplant in the next 6 months.~12. The patient does not have a mechanical triscupid heart valve.~13. The patient has not had a myocardial infarction, unstable angina, percutaneous coronary intervention, or coronary artery bypass graft during the preceding 30 days prior to enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).